Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis

Hepatitis B virus reactivation associated with ruxolitinib

(2013) Chien-Heng Shen et al.   ANNALS OF HEMATOLOGY

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

(2013) A. Heine et al.   BLOOD

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

(2013) G Caocci et al.   LEUKEMIA

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib

(2013) Rowan Wathes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib

(2013) Roger A. Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

(2012) Ayalew Tefferi   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed

(2009) Elizabeth A. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION